EGFR and neoplasm: For example, a synergistic effect is observed by a combination of gefitinib (EGFR inhibitor) with vorinostat (HDAC inhibitor) by enhancing tumour growth inhibition and apoptosis compared with monotherapy of selective EGFR inhibitors9,.10